Sign in

CIK 0001124105

  • Accelerated filer
  • Smaller reporting company

GYRE THERAPEUTICS, INC.

Sign in to watch
Ticker
GYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
562020050
Phone
+1 858-284-0115
Business address
12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
Former names
CATALYST BIOSCIENCES, INC., TARGACEPT INC
  1. 4 Planned sale President sold 2,182 shares at an average $10.91 ($23,804)
  2. 4 Planned sale President sold 4,000 shares at an average $11.04 ($44,160)
  3. 4 Planned sale President sold 4,000 shares at an average $11.21 ($44,840)
  4. 4 Planned sale President sold 2,020 shares at an average $10.69 ($21,586)
  5. 4 Exercise or conversion Chief Operating Officer acquired 50,000 shares (option exercise)
  6. 4 Planned sale President sold 4,000 shares at an average $10.97 ($43,860)
  7. 4 Exercise or conversion Chief Operating Officer acquired 650,000 shares (option exercise)
  8. 4 Exercise or conversion Director acquired 15,000 shares (option exercise)
  9. 4 Planned sale President sold 174 shares at $10.00 ($1,740)
  10. 4 Planned sale President sold 4,000 shares at an average $10.11 ($40,440)
  11. 4 Planned sale President sold 2,242 shares at an average $11.89 ($26,658)
  12. 4 Planned sale President sold 4,000 shares at an average $12.06 ($48,220)
  13. 4 Planned sale President sold 4,000 shares at an average $11.57 ($46,280)
  14. 4 Derivatives Options or other derivatives
  15. 4 Planned sale President sold 4,000 shares at an average $10.19 ($40,776)
  16. 4 Planned sale President sold 4,000 shares at an average $10.89 ($43,560)
  17. 4 Planned sale President sold 4,000 shares at an average $11.05 ($44,180)
  18. 4 Planned sale President sold 4,000 shares at an average $11.37 ($45,480)
  19. 4 Planned sale President sold 4,000 shares at an average $11.50 ($46,000)
  20. 4 Planned sale President sold 4,000 shares at an average $11.30 ($45,190)

Page 3 of 37 · 739 filings